Evidence strength for the context described on this page.
PEPTIDE ATLAS / MUSCLE & RECOVERY / TB-500
EvidenceInsufficienti
RegulatoryNot FDA-approvedi
TB-500

A thymosin beta-4 fragment with reported human use but no established healing or performance benefit.
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read the evidence limits
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
This peptide does not have an FDA-approved product or dose for the claims described here. Research dosing and vendor protocols are not consumer prescribing guidance.
The five facts to know first.
Status is product-, formulation- and indication-specific.
Public education does not establish a personal treatment plan.
Plus 1 research searches. A search link is not a cited study or proof of a claim.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗Where present, the date above records an editorial content review, not medical approval or a live check of every claim. Follow the official product label and regulator links for current status. This page does not establish availability through Modern Bio.
How we describe evidence →OVERVIEW
What TB-500 is.
TB-500 usually refers to the short LKKTETQ fragment, not pharmaceutical-grade full-length thymosin beta-4. Results from one molecule should not be casually assigned to the other.
Marketed around actin regulation, cell migration, blood-vessel formation and wound repair; clinical translation is unestablished.
The October 2026 HHS appendix specifies TB-500 acetate in subcutaneous or intramuscular injectable forms. Its conditional policy requires defined identity, quality controls and patient-specific prescriptions. The Federal Register describes it as draft and nonbinding. It is not FDA approval, a final 503A listing, or proof of safety or effectiveness, and does not establish Modern Bio access.
Read the HHS identity, route and policy conditions ↗This checks the stated regulatory point only, not every clinical claim in the profile.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- No established human healing or performance benefit for TB-500
- Tendon, ligament or muscle regeneration
- Faster return to sport
- Safety of repeated injection
- Equivalence to thymosin beta-4 studied in research
FDA’s safety-risk page reports no identified human-exposure data for TB-500 drug products. HHS’s October 2026 Appendix B describes documented historical compounded use. These are different records: reported use does not establish clinical benefit, comprehensive safety or a validated regimen. Human studies of full-length thymosin beta-4 cannot establish the fragment’s benefits.
Read HHS Appendix B alongside the FDA safety assessment ↗Evidence grade: Insufficient. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
CLINICAL CONTEXT
The decision is individual.
Research interest does not establish an approved treatment, a safe personal regimen or reliable product quality. Discuss established alternatives with a qualified clinician.
Identify the outcome, formulation and population actually studied.
Review benefits, uncertainty, contraindications and better-studied alternatives.
A treatment decision needs a responsible clinician, monitoring and a review date.
This public guide does not provide a dosing, injection or self-treatment protocol. Bring the source links and the exact product into a licensed clinical consultation.
MONITORING
What should be tracked.
- No validated monitoring program
- Injury-specific rehabilitation and clinical reassessment remain the standard
SAFETY
Risks, red flags and reasons to avoid it.
- Immunogenicity and peptide impurities
- Unknown systemic effects
- Contamination and sterility failures
- Potential anti-doping consequences for competitive athletes
- Self-injection
- Active cancer or unexplained mass
- Pregnancy
- Using it in place of rehabilitation
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
SOURCES & RESEARCH LINKS
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. Vendor and community dosing protocols are excluded from this public source list. These are supporting reading links, not a completed claim-by-claim citation map. Search links can lead to changing results; their presence does not establish that a particular study supports this profile.
PRODUCTS & TREATMENT ACCESS
There is no product we can responsibly recommend.
Not FDA-approved. An October 2026 HHS draft, nonbinding policy describes conditional enforcement discretion for specified compounded products. It does not establish approval, safety, effectiveness or availability through Modern Bio. See the dated regulatory note and official source.
Sellers frequently blur full-length thymosin beta-4 and its fragment. That is a scientific and product-identity problem, not a minor naming issue.
Evidence before affiliate revenue.
We do not rank or sell unapproved research peptides. Use the Atlas to discuss safer, evidence-backed alternatives with a qualified clinician.
Explore evidence-backed options →NEXT STEP
Return to muscle & recovery peptides.
Explore the category →YOUR NEXT STEP
Ready for a clinician-led plan?
Clinical review determines the appropriate next step. No treatment is guaranteed.
THE CARE PATH
We order your labs
A licensed clinician reviews results and recommends a plan
Rx sent directly to you when appropriate
Care depends on eligibility and clinical judgment. No prescription is guaranteed. This pathway is not a recommendation for the treatment or test discussed in this guide.
Start your lab reviewExplore free educational tools